Life Science Intelligence Blog

LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.

This week in medtech deals an estimated over $297.6 million in funding was raised across 10 deals, in addition to a number of other undisclosed deals that were announced. Here are some of the top deals tracked:

Start a Free Trial to Medtech Startup Tracker Today

Medical Devices & Diagnostics (MD&D) companies know they are being impacted by the current pandemic and are seeking independent research to quantify how much their markets will decline or increase, how long the recovery will take, and what factors will determine that recovery.

This new study quantifies and forecasts the impact of the Coronavirus pandemic on key medical devices & diagnostics markets and the suppliers to those industries.

The global market for respirator masks was estimated to be 5 billion units per year prior to the outbreak and is now expected to exceed 100 billion units in 2020; assuming the virus will be contained and the incidence of new infections subsides by end of 2020. The price of masks has been soaring and are selling at more than 10 times standard prices in many cases. China has been the main supplier of personal protection equipment, which further complicates the current market dynamics.

Life Science Intelligence (LSI) has been tracking and publishing market data on the global surgical apparel market and protective personal equipment (PPE) market for the last decade. LSI’s new market report, Global Opportunities in Surgical Masks and Respirators Market - Impact Analysis of Coronavirus Outbreak provides a reliable and independent forecast of the COVID-19 impact to these markets.

In the latest report available in LSI's Medtech Pro Platform, Impact of 2020 Crisis on Global Medical Devices & Diagnostics Market, new forecasts and analysis based on the impact of COVID-19 are provided. More specifically, the report details the impact of the crisis annually for 2020 through 2025 on:

The presence of an arrhythmia is confirmed when the heart beats at an irregular rate. Persistent arrhythmia necessitates clinical evaluation and may require some form of intervention to prevent the irregularity from becoming life-threatening. When left untreated, serious forms of arrhythmia can lead to serious complications, such as stroke and heart failure. Recurring arrhythmia can be managed with a number of therapeutic options, including pharmaceuticals, implantable devices (e.g. pacemakers), and ablative procedures.

Stroke is the second largest cause of death globally, claiming an estimated 5.5 million lives annually. The burden of stroke is expected to worsen in the future as a result of demographic and lifestyle changes in developed and developing countries. During the acute stage there are several pharmaceuticals and surgical procedures available to assist healthcare providers manage stroke patients. This market research report provides forecasts and analysis of the embolization products used in the management and treatment of stroke. In addition to market forecasts, this report provides insights into the leading competitors in the cerebral embolization products market.

The ambitious goal for healthcare in Brazil is “health for all”. Formed in 1988, Brazil’s Sistema Único da Saúde (SUS) is one of the largest public health systems in the world. Universal healthcare in Brazil is funded through local and federal taxes provided by government and private institutions. The SUS ensures that Brazilian residents and foreigners in Brazil have access to public healthcare. It is estimated that 75% of Brazil’s 200+ million residents is reliant on the SUS for access to healthcare.

Healthcare in Europe parallels the US healthcare system in many ways. Western Europe faces significant challenges when it comes to determining how to efficiently meet the demand for more healthcare to an aging population with an increasing burden of age-related chronic diseases. Simultaneously, the issues of how to keep costs down and affordable to patients continues to test the healthcare sector in the five major European markets (France, Germany, Italy, Spain, United Kingdom). However, these problems are not unique to the five largest economies in Europe. These challenges pervade all countries within the European Union.